



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/936,499
Filing Date	09/12/2001
First Named Inventor	Stephen B. Liggett
Art Unit	4634
Examiner Name	Goldberg
Attorney Docket Number	MWH-0031US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]
$$8/26/03$$

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/936,499
Filing Date	09/12/2001
First Named Inventor	Stephen B. Liggett
Group Art Unit	
Examiner Name	
Attorney Docket Number	MWH-0031US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S.B.	BA	GREEN, S.B. ET AL., "Influence of B2-Adrenergic Receptor Genotypes on Signal Transduction in Human Airway Smooth Muscle Cells," Am. J. Respir. Cell Mol. Biol., Vol. 13, p. 25-33, (1995).	
	BB	GREEN, S.B. ET AL., "Amino-Terminal Polymorphisms of the Human B2-Adrenergic Receptor Impart Distinct Agonist-Promoted Regulatory Properties," Biochemistry, Vol. 33, p. 9414-9419, (1994).	
	BC	GREEN, S.B. ET AL., "A Polymorphism of the Human B2-Adrenergic Receptor within the Fourth Transmembrane Domain Alters Ligand Binding and Functional Properties of hte Receptor," The Journal of Biological Chemistry, Vol. 268, p.23116-21, (1993).	
	BD	HALL, IAN ET AL., "Association of Glu27 B2-Adrenoceptor Polymorphism with Lower Airway Reactivity in Asthmatic Subjects," The Lancet, Vol. 345, p. 1213-4, (1995).	
	BE	LIGGETT, S.B., "Functional Properties of Human B2-Adrenergic Receptor Polymorphisms," News in Physiological Sciences, Vol. 10, p. 265-273, (1995).	
	BF	LIGGETT, S.B., "The Genetics of B2-Adrenergic Receptor Polymorphisms: Relevance to Receptor Fuction and Asthmatic Phenotypes," The Genetics of Asthma, 1st ed., Marcel Dekker (New York), p. 455-478, (1996).	
	BG	LIGGETT, S.B. ET AL., "The Ile164 B2-Adrenergic Receptor Polymorphism Adversely Affects the Outcome of Congestive Heart Failure," J. Clin. Invest., Vol. 102 (No. 8), p. 1534-1539, (1998).	
	BH	LIGGETT, S.B., "Polymorphisms in the 5' Leader Cistron of the B2-Adrenergic Receptor," Pending U.S. Application, Serial No.09/856,803, (Filed May 25, 2001).	
	BI	MCGRAW, D.W. ET AL., "Polymorphisms in the 5' Leader Cistron of the Human B2-Adrenergic Receptor Regulate Receptor Expression," J. Clin. Invest., Vol. 102 (No. 11), p. 1927-1932, (1998).	
	BJ	REIHS AUS, ELLEN ET AL., "Mutations in the Gene Encoding for the B2-Adrenergic Receptor In Normal and Asthmatic Subjects," Am. J. Respir. Cell Mol. Biol., Vol. 8, p. 334-339, (1993).	
	BK	TURKI, JAMAL ET AL., "Genetic Polymorphism of the B2-Adrenergic Receptor in Nocturnal and Nonnocturnal Asthma," J. Clin. Invest., p. 1635-1641, (1995).	

Examiner Signature	<u>S. Goldberg</u>	Date Considered	<u>8/26/03</u>
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

2003

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

09/936.499

Filing Date

09/12/2001

First Named Inventor

Stephen B. Liggett

Art Unit

~~1623~~ 1634

Examiner Name

Goldberg

Attorney Docket Number

MWH-0031US

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

J. Goldberg

Date _____

Considered

8/26/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.